BOLT: boltbio.com Company Value to Net Income

Bolt Bio - graphic logo of issuer BOLT

This daily price chart for Bolt Biotherapeutics (BOLT), which carries a multiplier of -0.40, reflects market expectations for the immune drug developer. Business success relies on the confirmed efficacy of antibodies in tumor therapy, the safety of methods, and partnerships with industry behemoths. Growth is driven by breakthroughs in ISAC-conjugate development and cost reductions, while the R&D center updates platforms following the closure of legacy programs.

boltbio.com (BOLT) Price to Earnings Ratio: for the period 07/04/2022 - 11/12/2026

Analytical breakdowns for Bolt Biotherapeutics Inc. (BOLT)

- price and consensus price forecast:
Stock Price Bolt Bio|BOLT - Consensus Target
- market capitalization information:
Market Value Bolt Biotherapeutics, Inc.|BOLT - Enterprise Value
- balance sheet net asset value indicators:
Net Assets per Share Bolt Biotherapeutics|BOLT - Company Book Value|Market Cap to Net Assets Ratio boltbio.com|BOLT - Aggregate Company Assets
- debt and solvency information:
Total Debt to Equity Ratio Bolt Biotherapeutics|BOLT - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Bolt Bio|BOLT - Company Debts|Debt to Book Value Ratio Bolt Biotherapeutics, Inc.|BOLT - Company Long-Term Debts|Short-Term Debt Bolt Biotherapeutics|Quick Liquidity boltbio.com
- earnings and market multiples details:
BOLT - Company Net Income|Expected Net Profit Bolt Biotherapeutics|BOLT - Price to Earnings Ratio|Future Price to Earnings Bolt Bio|BOLT - Price/Earnings to Growth Multiple|Enterprise Value to Operating Income Before Depreciation Ratio Bolt Biotherapeutics, Inc.|BOLT - Operating profit before deduction of amortization|Earnings per share for the trailing year Bolt Biotherapeutics|BOLT - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months boltbio.com|BOLT - Earnings growth in current year|Consensus forecast of earnings per share growth for next year Bolt Biotherapeutics
Comprehensive company analysis:boltbio.com BOLT
Signature product of Bolt Biotherapeutics Inc.

The P/E ratio determines investment reliability by comparing a stock's market value with the company's net income to estimate the payback period. By analyzing the P/E trajectory of Bolt Biotherapeutics (BOLT), an investor can identify overpayment risks, which is critical for Bolt Biotherapeutics during its period of restructuring and shift in research focus following the failure of a key oncology drug and large-scale workforce reductions.

Key competitors

P/E Multiple argenx.com|Price to Earnings Ratio BNTX (BioNTech)|ABVX (ABIVAX) - Company Value to Net Income|P/E Multiple ADMA (ADMA Bio)|Business Payback Period Protagonist Corp (PTGX)|IMVT - Price to Earnings Ratio|kiniksa.com (KNSA) - Price to Earnings Ratio|Grifols (GRFS) - Price to Earnings Ratio|Price to Earnings Ratio Adaptive Biotech|Price to Earnings Ratio CLDX|P/E Multiple Aurinia Corp|Price to Earnings Ratio BioCryst (BCRX)|veratx.com - Price to Earnings Multiple|P/E Multiple DNTH (Dianthus Therapeutics, Inc.)|Pharvaris NV (PHVS) - Market Cap to Earnings|AbCellera Bio - P/E Multiple|TRML: Price to Earnings Ratio|Precigen, Inc. (PGEN) - Price to Earnings Ratio|Market Cap to Earnings pharming.com (PHAR)|Price to Earnings Ratio Nektar Therapeutics Inc.|Price to Earnings Ratio UPB|Price to Earnings Ratio ZBIO (Zenas Biopharma, Inc.)|Market Price to Net Income Ratio IMNM|Gossamer Bio, Inc. - Price to Earnings Ratio|Company Value to Net Income KALV|Septerna - P/E Multiple|PVLA: Price to Earnings Ratio|SVRA: P/E Multiple|RIGL - Business Payback Period|Price to Earnings Ratio AnaptysBio, Inc.|Market Cap to Earnings astriatx.com ATXS|Price to Earnings Ratio ENGN (enGene)|Market Price to Net Income Ratio RAPT|P/E Multiple JBIO (Aerovate Therapeutics)|Company Value to Net Income ACRS|Kyverna Therapeutics - P/E Multiple|Market Cap to Earnings tizianalifesciences.com|Cabaletta Bio (CABA) - Price to Earnings Ratio|Ventyx Biosciences Inc. - Company Value to Net Income|THTX (Theratechnologies Inc) - P/E Multiple|P/E Multiple Avalo Therapeutics Inc|Price to Earnings Ratio Eledon Pharmaceuticals (ELDN)|AGEN: Market Cap to Net Income|P/E Multiple CLYM (Climb Bio)|Zura Bio Ltd (ZURA) - Market Cap to Earnings|ATYR: Price to Earnings Ratio|ADAG - P/E Multiple|IMA (ikenaoncology.com) - Price to Earnings Ratio|STTK: Market Price to Net Income Ratio|EQ (Equillium Inc) - P/E Multiple|Connect Pharma (CNTB) - Business Payback Period|P/E Multiple IMUX|Price to Earnings Ratio atarabio.com ATRA|Price to Earnings Ratio InflaRx IFRX|Business Payback Period x4pharma.com (XFOR)|Adicet - P/E Multiple|CELU: Price to Earnings Ratio|INmune Bio Corp (INMB) - Price to Earnings Ratio|Market Cap to Earnings Barinthus Biotherapeutics Corp (BRNS)|Price to Earnings Ratio Kezar Life Sciences|Price to Earnings Ratio SABS|Price to Earnings Ratio AKTX (Akari Therapeutics Plc)|Market Price to Net Income Ratio ENLV|Price to Earnings Ratio Q32 Bio QTTB|GOVX (GeoVax Corp) - Market Cap to Net Income|Edesa Biotech, Inc. - P/E Multiple|Company Value to Net Income IBIO (ibioinc.com)|CARM: P/E Multiple|XTL Biopharmaceuticals Ltd (XTLB) - P/E Multiple|Price to Earnings Ratio HCW Biologics, Inc.|APVO: Company Value to Net Income|Price to Earnings Ratio AIM ImmunoTech Inc. (AIM)|Price to Earnings Ratio aditxt.com ADTX|P/E Multiple GRI (GRI Bio)|P/E Multiple XORTX Therapeutics Inc XRTX|HIND: Price to Earnings Ratio|Company Value to Net Income REVB (Revelation Biosciences Corp)|INDP: P/E Multiple|SCNI - Business Payback Period|Price to Earnings Ratio CalciMedica Inc|Price to Earnings Ratio Affimed Therapeutics (AFMD)|Price to Earnings Ratio Allakos Inc. (ALLK)|Price to Earnings Ratio hookipapharma.com HOOK|IGM Biosciences - Price to Earnings Ratio|P/E Multiple iteostherapeutics.com ITOS|OCEA - Price to Earnings Ratio|TCBP (TC BioPharm (Holdings) Plc) - Price to Earnings Multiple|THRD: P/E Multiple